Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review evaluates the effectiveness and safety of various treatments for polycystic ovary syndrome including finasteride, flutamide, and metformin, but does not provide specific new results.

In this study, researchers observed that overweight Taiwanese women with PCOS who carry the HSD3B1 1245C allele have a significantly higher risk of developing androgenic alopecia compared to those with the wild-type allele.

In this study, researchers identified a causal link between Epstein-Barr virus infection and clear cell renal cell carcinoma, highlighting GBP1 as a key target and suggesting finasteride as a potential inhibitor, offering a new direction for treatment strategies.

This study found that genetic polymorphisms of OCT1 influence the effectiveness of metformin treatment in improving insulin sensitivity among PCOS patients, suggesting a role for personalized treatment strategies.

This study constructed a panel of pharmacokinetic and pharmacodynamic genes, revealing that current SNP chips insufficiently capture many drug-response gene variants, highlighting the need for complementary genetic approaches.

This study reported that using plain bottles instead of commercial kits for extracting platelet-rich plasma may be an effective method for treating hair loss.

A new genetic mutation causing Xeroderma Pigmentosum was found in an 8-year-old girl, affecting her DNA repair.

This study found that in patients with genetic generalized epilepsies, certain gene variants were linked to differences in valproic acid treatment outcomes, including a higher likelihood of treatment failure, varying serum drug concentrations, and specific side effects like weight gain and hair loss.

This study suggests that although the G972R variant of the IRS1 gene might increase AA excess risk in heterozygous carriers with CYP21 mutations, both variations play a limited role in PCOS development.

This study identified trilauric glyceride and decanoylcarnitine as potential biomarkers for diagnosing PCOS in patients with and without insulin resistance, suggesting significant metabolic alterations in these conditions.

This study found that women with polycystic ovary syndrome have significantly higher plasma levels of thrombin-activatable fibrinolysis inhibitor and other hemostatic markers compared to age- and BMI-matched healthy controls.

This study found that VDR polymorphisms, particularly ApaI and FokI variants, are associated with hormonal and metabolic disturbances in women with PCOS, with notable variations across different ethnicities.

This study found no evidence that CTLA-4 gene polymorphism (rs733618) plays a role in polycystic ovarian syndrome among the participants.

This study found that medroxyprogesterone acetate and ethinyl estradiol with drospirenone were the most frequently prescribed medications for PCOS, with some patients experiencing drug changes or discontinuation due to side effects or therapeutic failure.

This report describes a Cronkhite-Canada syndrome patient with severe sepsis and disseminated intravascular coagulation successfully treated using combined therapies, including recombinant human soluble thrombomodulin.

This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.

This study found that the ABCG2 (rs2231142) polymorphism was associated with an increased risk of hyperuricemia and hypercholesterolemia in young Mexican males.

This study observed that Nigerian women with PCOS have significantly higher levels of myocardial biomarkers (MYO, cTnI, CK-MB), indicating potential chronic, subclinical myocardial injury in this population.

This paper discusses the importance of early diagnosis and treatment of polycystic ovarian syndrome to potentially reduce long-term complications like diabetes, hypertension, and heart disease, but reports no new clinical outcomes.

This study used a newly developed RP-HPLC method to accurately measure finasteride distribution in human cadaver skin after applying different vesicular drug delivery systems.

This review discusses genetic and epigenetic studies of PCOS, highlighting Genome-Wide Association Studies that found genetic variants related to gonadotrophin secretion influencing PCOS susceptibility, but it reports no new findings.

This meta-analysis reported a significant association between vitamin D receptor gene ApaI polymorphism and polycystic ovary syndrome risk, with variations observed between Asian and Caucasian populations.

In this study, researchers found that unexplained liver damage in PCOS patients may involve iron metabolism and the miR-761-hepcidin/GPX4 axis, suggesting potential therapeutic targets.

This study reports that Ca 2+ binding alters the dynamics and surface properties of PKD-like domains in Clostridium histolyticum collagenases, enhancing their stability and potentially aiding in collagen-targeting vehicle development.

This study found that women with PCOS and factors like primary infertility, familial history of type 2 diabetes, and specific lipid profiles tend to have less favorable fertility treatment outcomes.

Certain variations of the HDAC9 gene can increase or decrease stroke risk in the Chinese population.

This study concluded that STK11 gene polymorphisms were not predictive of metformin response in women with PCOS, though they may influence alopecia and hirsutism.

The researchers reported that lifestyle changes and medications significantly impact managing PCOS, highlighting the high prevalence of cardiovascular comorbidities and the common risk factor of high BMI in these patients.

This study identified a novel pathogenic splice-site variant of the LAMB3 gene in patients with junctional epidermolysis bullosa, highlighting the importance of gene sequencing for diagnosis.

This study found that the rs1128977 SNP in the RXRG gene may be linked to altered clinical characteristics such as higher HDL-cholesterol levels and increased body mass index in individuals with dyslipidemia.